Skip to main content

Advertisement

SpringerLink
Log in

Pediatric Ocular Myasthenia Gravis

  • Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

We present a review of current strategies in the treatment of pediatric ocular myasthenia gravis (OMG). A critical appraisal was performed of the current literature available on OMG and the treatment options available for all age populations. From this data, we present the evidence surrounding therapeutic options for pediatric OMG and discuss treatment outcomes in the pediatric population. We also present gaps in the literature with regard to pediatric OMG and possibilities for future research.

Recent findings

While there is data on the use of steroid-sparing immunosuppressive agents for myasthenia gravis (MG), as a whole it is more specific for the use in generalized juvenile myasthenia gravis (JMG) and more focused toward the adult population. In the currently available literature, there have been reports published on the use of steroid-sparing agents including azathioprine, cyclosporine, and mycophenolate mofetil. A recent open-label trial has provided evidence for the use of tacrolimus to improve symptoms of JMG including OMG that were refractory to prednisone. In addition to this, there has been evidence that thymectomy is effective in controlling pediatric OMG and shows a pattern toward preventing generalization of MG, reducing prednisone dosing, and increasing resolution of disease. There are other treatments used in the pediatric population of MG, including intravenous immunoglobulin (IVIG), plasmapheresis, and rituximab, but currently there are no reports on use in OMG.

Summary

In the population of patients with pediatric OMG, a high percentage of patients are able to obtain stabilization of symptoms using only pyridostigmine or pyridostigmine in combination with oral prednisone. Rates of generalization of OMG range from 15 to 35%, with higher rates in the adolescent population, but approximately 25% of pediatric patients with OMG can have complete remission. For pediatric OMG patients with ophthalmologic manifestations that are refractory to pyridostigmine and prednisone, the use of steroid-sparing agents has been practiced more recently. In addition to this, thymectomy has been utilized in this population. In both of these instances, no pediatric randomized control trials have been performed to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Phillips LH, Torner JC, Anderson MS, Cox GM. The epidemiology of myasthenia gravis in central and western Virginia. Neurology. 1992;42(10):1888–93.

    Article  Google Scholar 

  2. Andrews PI. Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1):101–10.

    Article  CAS  Google Scholar 

  3. Vanderpluym J, Vajsar J, Jacob FD, Mah JK, Grenier D, Kolski H. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics. 2013;132(4):e939–44.

    Article  Google Scholar 

  4. Kim JH, Hwang JM, Hwang YS, Kim KJ, Chae J. Childhood ocular myasthenia gravis. Ophthalmology. 2003;110(7):1458–62.

    Article  Google Scholar 

  5. Pineles SL, Avery RA, Moss HE, et al. Visual and systemic outcomes in pediatric ocular myasthenia gravis. Am J Ophthalmol. 2010;150(4):453–459.e3.

    Article  Google Scholar 

  6. •• Vanikieti K, Lowwongngam K, Padungkiatsagul T, Visudtibhan A, Poonyathalang A. Juvenile ocular myasthenia gravis: presentation and outcome of a large cohort. Pediatr Neurol. 2018;87:36–41 A recent large cohort of juvenile patients with OMG is reported in this article, discussing symptom presentation and treatment outcomes.

    Article  Google Scholar 

  7. Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg. 2011;92(6):1993–9.

    Article  Google Scholar 

  8. Motobayashi M, Inaba Y, Nishimura T, Kobayashi N, Nakazawa Y, Koike K. An increase in circulating B cell-activating factor in childhood-onset ocular myasthenia gravis. Pediatr Neurol. 2015;52(4):404–9.

    Article  Google Scholar 

  9. •• Liu C, Gui M, Cao Y, et al. Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatr Neurol. 2017;77:42–7 Recent study published on the use of tacrolimus in 14 children with MG and its effectiveness.

    Article  Google Scholar 

  10. • Smith SV, Lee AG. Update on ocular myasthenia gravis. Neurol Clin. 2017;35(1):115–23 Recent relevant review on OMG, diagnostic modalities, and treatment options.

    Article  Google Scholar 

  11. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology. 2000;107(3):504–10.

    Article  CAS  Google Scholar 

  12. Lee HN, Kang HC, Lee JS, Kim HD, Shin HY, Kim SM, et al. Juvenile myasthenia gravis in Korea: subgroup analysis according to sex and onset age. J Child Neurol. 2016;31(14):1561–8.

    Article  Google Scholar 

  13. Mittal MK, Barohn RJ, Pasnoor M, McVey A, Herbelin L, Whittaker T, et al. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response. J Clin Neuromuscul Dis. 2011;13(1):46–52.

    Article  Google Scholar 

  14. Ortiz S, Borchert M. Long-term outcomes of pediatric ocular myasthenia gravis. Ophthalmology. 2008;115(7):1245–1248.e1.

    Article  Google Scholar 

  15. Peragallo JH, Velez FG, Demer JL, Pineles SL. Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis. J Neuroophthalmol. 2013;33(1):40–4.

    Article  Google Scholar 

  16. Park KA, Oh SY. Treatment for diplopia in patients with myasthenia gravis. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):895–901.

    Article  Google Scholar 

  17. Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthalmic Plast Reconstr Surg. 2001;17(2):103–10.

    Article  CAS  Google Scholar 

  18. • Brogan K, Farrugia ME, Crofts K. Ptosis surgery in patients with myasthenia gravis: a useful adjunct to medical therapy. Semin Ophthalmol. 2018;33(3):429–34 A report of patients with persistent ptosis in MG who have undergone surgical correction and discussion of the benefits and outcome of the procedure.

    Article  Google Scholar 

  19. • Belliveau MJ, Oestreicher JH. Ptosis repair in ocular myasthenia gravis. Semin Ophthalmol. 2017;32(5):564-8 Additional case series of patients with OMG and persistent ptosis who have undergone surgical repair and the outcomes related to the procedure.

    Article  Google Scholar 

  20. Pruitt JA, Ilsen PF. On the frontline: what an optometrist needs to know about myasthenia gravis. Optometry. 2010;81(9):454–60.

    Article  Google Scholar 

  21. Han J, Han SY, Han SH, Lee JB. Strabismus surgery and long-term visual outcomes in patients with preadolescent onset ocular myasthenia gravis. Graefes Arch Clin Exp Ophthalmol. 2015;253(1):157–63.

    Article  Google Scholar 

  22. Kerty E, Elsais A, Argov Z, Evoli A, Gilhus NE. EFNS/ENS guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687–93.

    Article  CAS  Google Scholar 

  23. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010;43(5–6):428–35.

    Article  CAS  Google Scholar 

  24. Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48(2):95–104.

    Article  Google Scholar 

  25. Ishigaki K, Shishikura K, Murakami T, Suzuki H, Hirayama Y, Osawa M. Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis. Brain Dev. 2009;31(8):634–7.

    Article  Google Scholar 

  26. Ware TL, Ryan MM, Kornberg AJ. Autoimmune myasthenia gravis, immunotherapy and thymectomy in children. Neuromuscul Disord. 2012;22(2):118–21.

    Article  Google Scholar 

  27. • Ashfaq A, Bernes SM, Weidler EM, Notrica DM. Outcomes of thoracoscopic thymectomy in patients with juvenile myasthenia gravis. J Pediatr Surg. 2016;51(7):1078–83 A relevant case series on outcomes of patients with MG who have undergone thymectomy and discussion of efficacy of thymectomy.

    Article  Google Scholar 

  28. Hennessey IA, Long AM, Hughes I, Humphrey G. Thymectomy for inducing remission in juvenile myasthenia gravis. Pediatr Surg Int. 2011;27(6):591–4.

    Article  Google Scholar 

  29. •• Kim AG, Upah SA, Brandsema JF, Yum SW, Blinman TA. Thoracoscopic thymectomy for juvenile myasthenia gravis. Pediatr Surg Int. 2019;35(5):603–10 Most recent and largest cohort of juvenile patients who have undergone thymectomy, discussion of outcomes and evidence relating to efficacy of the procedure.

    Article  Google Scholar 

  30. •• Zhu K, Li J, Huang X, et al. Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis. Neurol Sci. 2017;38(10):1753–60 This article specifically discusses the outcomes of patients with OMG who have undergone thymectomy, review of literature, and review of patients.

    Article  Google Scholar 

  31. •• Catalano MA, Mullan CW, Rich BS, Glick RD. Pediatric thymectomy: a study of national trends in demographics, short-term outcomes, and cost. Pediatr Surg Int. 2019;35(7):749–57.A cross-sectional analysis looking at thymectomy in the pediatric population, safety, and outcomes with the procedure.

    Article  Google Scholar 

  32. Kaba E, Cosgun T, Ayalp K, Toker A. Robotic thymectomy for myasthenia gravis. Ann Cardiothorac Surg. 2019;8(2):288–91.

    Article  Google Scholar 

  33. Selcen D, Dabrowski ER, Michon AM, Nigro MA. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40–3.

    Article  CAS  Google Scholar 

  34. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr. 2003;143(5):674–7.

    Article  Google Scholar 

  35. Tzaribachev N, Koetter I, Kuemmerle-deschner JB, Schedel J. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J. 2009;2:6609.

    Article  Google Scholar 

  36. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41(3):375–8.

    Article  CAS  Google Scholar 

  37. Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367–76.

    Article  CAS  Google Scholar 

  38. Edmundson C, Guidon AC. Eculizumab: a complementary addition to existing long-term therapies for myasthenia gravis. Muscle Nerve. 2019;60(1):7–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Texas Children’s Hospital, Baylor College of Medicine, 6701 Fannin Street- 5th floor Suite 610.25, Houston, TX, 77478, USA

    Kristen Fisher DO & Veeral Shah MD, PhD

Authors
  1. Kristen Fisher DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Veeral Shah MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veeral Shah MD, PhD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurologic Ophthalmology and Otology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fisher, K., Shah, V. Pediatric Ocular Myasthenia Gravis. Curr Treat Options Neurol 21, 46 (2019). https://doi.org/10.1007/s11940-019-0593-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-019-0593-y

Keywords

Search

Navigation